Spyre Therapeutics, Inc.
NASDAQ:SYREBiotechnology
Healthcare
$97.63 +1.38%
+$1.21 today
- Market cap
- $9.27B
- Beta
- 3.06
- P/E (TTM)
- -171.1
- EPS (TTM)
- -$0.52
52W Low $14.00High $91.04
Volume 0.63M
Average 1.17M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$209.56M
FY 2025 · Annual
Net Income
-$155.20M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.74M | 2.33M | 886K | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 171.65M |
| Gross Profit | 18.74M | 2.33M | 886K | 0 | (171.65M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Research & Development | 57.07M | 58.58M | 89.5M | 162.79M | 171.65M |
| Selling, General & Admin | 27.32M | 28.53M | 39.95M | 45.78M | 47.91M |
| Operating Expenses | 84.39M | 87.11M | 243.19M | 208.57M | 37.91M |
| Depreciation & Amortization | 1.58M | 1.96M | 744K | 0 | 10M |
| EBITDA | (64.08M) | (81.99M) | (127.82M) | (207.97M) | (209.56M) |
| EBITDA Margin | -342.0% | -3520.3% | -14426.6% | — | — |
| Operating Income | (65.65M) | (84.78M) | (242.3M) | (208.57M) | (209.56M) |
| Operating Margin | -350.3% | -3640.2% | -27348.0% | — | — |
| Interest Income | 111K | 837K | 6.15M | 21.31M | 24.89M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (11K) | 830K | (96.51M) | 599K | 54.34M |
| Income Before Tax | (65.66M) | (83.95M) | (338.82M) | (207.97M) | (155.22M) |
| Pre-Tax Margin | -350.4% | -3604.6% | -38241.1% | — | — |
| Income Tax Expense | 141K | (136K) | (26K) | 51K | (15K) |
| Net Income | (65.8M) | (83.82M) | (338.79M) | (208.02M) | (155.2M) |
| Net Margin | -351.1% | -3598.8% | -38238.1% | — | — |
| EPS (Basic) | (25.02) | (24.86) | (46.15) | (3.18) | (1.98) |
| EPS (Diluted) | (25.02) | (24.86) | (46.15) | (3.18) | (1.98) |
| 2.63M | 3.37M | 6.9M | 47.03M | 64.06M | |
| 2.63M | 3.37M | 6.9M | 47.03M | 64.06M |
SYRE Earnings Waterfall · TTM
NASDAQ:SYRE · Revenue to Net Income
Key Ratios
EPS$-2.74
Gross Margin12.5%
Net Margin-17.3%
P/E Ratio-28.5
P/S Ratio6.8
Analysis
$90.5M of revenue converted into -$263.9M of net income for the selected period. Gross margin is 12.5% and net margin is -17.3%, showing how much revenue survives after costs and taxes. EPS is $-2.74, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | |
| 8-K | Current report | Nov 3, 2026 | |
| SC 13D/A | SC 13D/A filing | Oct 9, 2026 | |
| 8-K | Current report | Oct 7, 2026 | |
| 424B5 | 424B5 filing | Oct 6, 2026 |
How much revenue does SYRE generate?
Spyre Therapeutics, Inc. (SYRE) reported $0.00 of revenue in fiscal 2025.
Is SYRE profitable?
Spyre Therapeutics, Inc. (SYRE) reported -$155.20M of net income.
Continue the stock analysis
Jump to another research area for this company.